FFO
TRDA icon

Fortitude Family Office’s Entrada Therapeutics TRDA Stock Holding History

Fortitude Family Office’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37
Closed -$334 – 2134
2025
Q1 		$334 Hold
37
– – ﹤0.01% 1098
2024
Q4 		$640 Buy
+37
New +$670 ﹤0.01% 1199

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Fortitude Family Office's TRDA Position: Q2 2025 in Review

Fortitude Family Office sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 37 shares — an estimated $334 sold.

Fortitude Family Office first reported a position in TRDA in Q4 2024 and held it in 2 quarters. The position peaked at $640 in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Fortitude Family Office reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Fortitude Family Office sold 37 Entrada Therapeutics shares in Q2 2025, an estimated $334.
  • Fortitude Family Office first reported a position in Entrada Therapeutics in Q4 2024 and held it in 2 quarters.
  • Fortitude Family Office's Entrada Therapeutics position peaked at $640 in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Fortitude Family Office's 13F filing for Q2 2025, filed 15 Jul 2025.